Dig Dis Sci:新诊断为炎症性肠病的年轻患者的骨密度明显偏低

2021-02-09 MedSci原创 MedSci原创

以溃疡性结肠炎(UC)和克罗恩病(CD)为主的炎症性肠病(IBD)被认为是胃肠道的慢性非特异性炎症。这种情况可能导致营养物质吸收不良,并引起并发症。

      溃疡性结肠炎(UC)和克罗恩病(CD)为主的炎症性肠病(IBD)被认为是胃肠道的慢性非特异性炎症。这种情况可能导致营养物质吸收不良,并引起并发症,例如骨质减少和骨质疏松。许多报告表明,与普通人群相比,IBD患者的骨质疏松症和骨质疏松症患病率较高,双能X射线骨密度仪(DXA)可以估算骨密度(BMD),而骨矿物质密度在确定骨强度中起着不可或缺的作用。许多研究人员认为,低BMD的临床危险因素是小肠切除术史,低体重指数(BMI),使用皮质类固醇激素,营养不良(包括钙和维生素D缺乏),IBD的病程以及吸烟等等。IBD患者低BMD的发病机制是多因素的,尚未完全揭示。因此,本项研究旨在探究新诊断为IBD的韩国年轻患者中低BMD的患病率和危险因素。

 

 

      研究人员在2014年11月至2017年4月之间从韩国6个三级转诊中心招募了132名年龄小于50岁且新诊断为IBD的患者。通过双能X射线吸收法测量BMD,然后确定Z评分。低BMD的定义为Z分数≤−1.0。然后对所有患者进行统计学分析。

 

 

      在68例溃疡性结肠炎(UC)患者中,有22例(32.4%)处于BMD较低水平。另外,在64名克罗恩病(CD)患者中,有24名(37.5%)的BMD较低。多元回归分析的结果确定了UC患者低BMD的危险因素是碱性磷酸酶(ALP)水平较高(≥140 U / L)(P =0.010),以及体重过轻(体重指数≤18.5 kg/m2)。

 

      大约三分之一的新诊断为IBD的亚洲患者的BMD处于较低水平。与低BMD相关的临床因素是UC患者的ALP水平高,而CD患者是体重过轻。因此,在诊断IBD时应考虑对年轻患者的BMD进行测量。

 

 

 

原始出处:

Joon Seop Lee. Et al. Low Bone Mineral Density in Young Patients Newly Diagnosed with Inflammatory Bowel Disease. Digestive Diseases and Sciences.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1915309, encodeId=806019153097c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 18:07:35 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013580, encodeId=b22e20135804b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 18 01:07:35 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525701, encodeId=dc0b1525e017e, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547414, encodeId=2369154e41401, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=)]
    2022-01-11 rgjl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1915309, encodeId=806019153097c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 18:07:35 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013580, encodeId=b22e20135804b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 18 01:07:35 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525701, encodeId=dc0b1525e017e, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547414, encodeId=2369154e41401, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=)]
    2021-06-18 zhaojie88
  3. [GetPortalCommentsPageByObjectIdResponse(id=1915309, encodeId=806019153097c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 18:07:35 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013580, encodeId=b22e20135804b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 18 01:07:35 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525701, encodeId=dc0b1525e017e, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547414, encodeId=2369154e41401, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1915309, encodeId=806019153097c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Tue Jan 11 18:07:35 CST 2022, time=2022-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013580, encodeId=b22e20135804b, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Jun 18 01:07:35 CST 2021, time=2021-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525701, encodeId=dc0b1525e017e, content=<a href='/topic/show?id=e96e489842a' target=_blank style='color:#2F92EE;'>#年轻患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48984, encryptionId=e96e489842a, topicName=年轻患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aab511654279, createdName=minzju5056, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1547414, encodeId=2369154e41401, content=<a href='/topic/show?id=4ef26e01766' target=_blank style='color:#2F92EE;'>#炎症性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67017, encryptionId=4ef26e01766, topicName=炎症性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=09e813968720, createdName=12498dd9m15暂无昵称, createdTime=Thu Feb 11 08:07:35 CST 2021, time=2021-02-11, status=1, ipAttribution=)]

相关资讯

Dig Dis Sci:成人炎症性肠病的睡眠特征和休息活动节律与胃肠道症状有关

炎症性肠病(IBD)是一种慢性免疫介导的疾病,其病情难以预测,在美国约有160万人深受折磨。

Dig Dis Sci:严重缺乏维生素D对炎症性肠病临床病程的影响

克罗恩病(CD)和溃疡性结肠炎(UC)是炎性肠病(IBD)的两种形式,是特发性的慢性复发性疾病,随着IBD在西方和东方国家的普及率不断提高。

Dig Dis Sci: 炎症性肠病不会影响死亡率,但会增加急性心肌梗死患者的住院时间

炎性肠病(IBD)是一种由免疫介导的慢性组织损伤的胃肠道(GI)炎性病症,主要包括溃疡性结肠炎(UC)和克罗恩病(CD)。

IBD:每天服用阿司匹林不会影响炎症性肠病患者的临床疗效

尽管有几项研究已证实非甾体类抗炎药的使用与炎症性肠病(IBD)患者的疾病发作存在相关性,但对每日服用阿司匹林对IBD患者临床结局的影响知之甚少。因此,本项研究旨在对此进行相关评估。

Dig Dis Sci:分娩方式不影响炎症性肠病的风险

以克罗恩病(CD)和溃疡性结肠炎(UC)为主的炎症性肠病(IBD)是胃肠道相关的慢性复发-缓解型炎症性疾病。

TAG:炎症性肠病患者使用维多珠单抗后粪便钙卫蛋白是内镜和组织学缓解的早期预测指标

维多珠单抗-Vedolizumab(VDZ)是一种抑制α4β7整联蛋白的肠道选择性人源化单克隆抗体,目前已经被FDA批准用于治疗溃疡性结肠炎(UC)和克罗恩病(CD)的成年患者。